Clinical Trial Detail

NCT ID NCT03196232
Title Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pamela L. Kunz
Indications

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

gastric adenocarcinoma

Therapies

Epacadostat + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.